Alto Neuroscience, Inc. (ANRO)
| Market Cap | 850.38M +1,277.7% |
| Revenue (ttm) | n/a |
| Net Income | -63.24M |
| EPS | -2.19 |
| Shares Out | 35.05M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,284 |
| Open | 24.26 |
| Previous Close | 24.26 |
| Day's Range | 23.76 - 24.45 |
| 52-Week Range | n/a |
| Beta | 1.65 |
| Analysts | Strong Buy |
| Price Target | n/a |
| Earnings Date | May 14, 2026 |
About ANRO
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 pro... [Read more]
Financial Performance
Financial StatementsNews
Alto Neuroscience initiated with a Buy at BofA
BofA analyst Tazeen Ahmad initiated coverage of Alto Neuroscience (ANRO) with a Buy rating and $35 price target The clinical-stage biotech company’s, ALTO-207, is in development for treatment-resistan...
Alto Neuroscience presents Phase 2a data for ALTO-207 in MDD
Alto Neuroscience (ANRO) announced the presentation of data from a randomized, single-blind, placebo-controlled Phase 2a trial of ALTO-207 in patients with Major Depressive Disorder, MDD. The data wer...
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, t...
Alto Neuroscience participates in a conference call with H. C. Wainwright
Healthcare Analyst Trucchio holds a conference call with CEO Etkin to discuss Alto’s precision psychiatry pipeline on May 5 at 12 pm hosted by H.C. Wainwright.Webcast Link Published first on…
Alto Neuroscience initiates Phase 2b trial of ALTO-207 in TRD
Alto Neuroscience (ANRO) announced the initiation of a Phase 2b randomized, placebo-controlled trial of ALTO-207 in treatment-resistant depression, a program designed to replicate the strongly positiv...
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, t...
Alto Neuroscience files to sell 6M shares of common stock for holders
16:03 EDT Alto Neuroscience (ANRO) files to sell 6M shares of common stock for holders
Alto Neuroscience’s ALTO-101 miss doesn’t impact thesis, says H.C. Wainwright
While Alto Neuroscience’s (ANRO) ALTO-101 failed to meet its Phase 2 primary endpoints in cognitive impairment associated with schizophrenia, the outcome does not alter H.C. Wainwright’s broader thesi...
Alto Neuroscience price target lowered to $21 from $22 at Wedbush
Wedbush lowered the firm’s price target on Alto Neuroscience (ANRO) to $21 from $22 and keeps a Neutral rating on the shares after the company reported top-line results from its…
Alto Neuroscience price target lowered to $38 from $41 at Baird
Baird analyst Brian Skorney lowered the firm’s price target on Alto Neuroscience (ANRO) to $38 from $41 and keeps an Outperform rating on the shares. The firm views the Phase…
Alto Neuroscience price target lowered to $44 from $49 at JonesResearch
JonesResearch analyst Justin Walsh lowered the firm’s price target on Alto Neuroscience (ANRO) to $44 from $49 and keeps a Buy rating on the shares after the company announced that…
Alto Neuroscience announces ALTO-101 did not achieve statistical significance
Alto Neuroscience (ANRO) announced topline data from its Phase 2 proof-of-concept clinical trial evaluating ALTO-101 for the treatment of cognitive impairment associated with schizophrenia, and provid...
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced ...
Alto Neuroscience price target raised to $41 from $22 at Baird
Baird analyst Brian Skorney raised the firm’s price target on Alto Neuroscience (ANRO) to $41 from $22 and keeps an Outperform rating on the shares. The firm updated its model…
Alto Neuroscience Transcript: Stifel 2026 Virtual CNS Forum
ALTO-207's combination therapy for TRD enables higher, faster dosing with robust efficacy and improved tolerability, supported by strong IP and rigorous trial execution. Multiple pipeline catalysts, including ALTO-101 and ALTO-300, are expected this year, with a cash runway through 2029.
Alto Neuroscience price target raised to $22 from $13 at Wedbush
Wedbush analyst Laura Chico raised the firm’s price target on Alto Neuroscience (ANRO) to $22 from $13 and keeps a Neutral rating on the shares. Most notable in Q4 results,…
Alto Neuroscience to sell 2.9M shares at $20.00 in private placement
Alto Neuroscience (ANRO) announced that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing for gross pr...
Alto Neuroscience Announces $120 Million Private Placement Financing
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines...
Alto Neuroscience reports FY25 EPS ($2.19) vs. ($2.50) last year
“Alto enters 2026 with a very strong clinical and financial foundation,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience (ANRO). “The acquisition of ALTO-207 is…
Alto Neuroscience sees cash runway into 2028
As of December 31, 2025, the Company had cash, cash equivalents, and restricted cash of approximately $177 million, compared to approximately $169 million in cash, cash equivalents, and restricted cas...
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines...
Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines ...
Alto Neuroscience Transcript: TD Cowen 46th Annual Health Care Conference
The presentation highlighted a precision psychiatry pipeline with late-stage programs for depression, TRD, bipolar depression, and cognition in schizophrenia. ALTO-207 and ALTO-101 are lead assets, with pivotal trials and key readouts expected through 2027. Biomarker-driven patient selection and innovative formulations aim to improve efficacy and tolerability.
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines ...
Alto Neuroscience price target raised to $28 from $27 at BTIG
BTIG analyst Thomas Shrader raised the firm’s price target on Alto Neuroscience (ANRO) to $28 from $27 and keeps a Buy rating on the shares. The firm cites the Alto…